encorafenib (Braftovi®) accepted for use within NHSScotland
The SMC has accepted encorafenib in combination with binimetinib for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
Source:
Scottish Medicines Consortium
SPS commentary:
NICE had also similarly approved encorafenib for this indication.